[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PL2040713T3 - Pochodne kwasów żółciowych jako ligandy FXR do zapobiegania lub leczenia chorób lub stanów, w których pośredniczy FXR - Google Patents

Pochodne kwasów żółciowych jako ligandy FXR do zapobiegania lub leczenia chorób lub stanów, w których pośredniczy FXR

Info

Publication number
PL2040713T3
PL2040713T3 PL07809913T PL07809913T PL2040713T3 PL 2040713 T3 PL2040713 T3 PL 2040713T3 PL 07809913 T PL07809913 T PL 07809913T PL 07809913 T PL07809913 T PL 07809913T PL 2040713 T3 PL2040713 T3 PL 2040713T3
Authority
PL
Poland
Prior art keywords
fxr
deseases
mediated
prevention
treatment
Prior art date
Application number
PL07809913T
Other languages
English (en)
Inventor
Roberto Pellicciari
Stefano Fiorucci
Mark Pruzanski
Original Assignee
Intercept Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38846269&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2040713(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intercept Pharmaceuticals Inc filed Critical Intercept Pharmaceuticals Inc
Publication of PL2040713T3 publication Critical patent/PL2040713T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL07809913T 2006-06-27 2007-06-27 Pochodne kwasów żółciowych jako ligandy FXR do zapobiegania lub leczenia chorób lub stanów, w których pośredniczy FXR PL2040713T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81663506P 2006-06-27 2006-06-27
EP07809913.2A EP2040713B1 (en) 2006-06-27 2007-06-27 Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated deseases or conditions
PCT/US2007/014829 WO2008002573A2 (en) 2006-06-27 2007-06-27 Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated deseases or conditions

Publications (1)

Publication Number Publication Date
PL2040713T3 true PL2040713T3 (pl) 2014-11-28

Family

ID=38846269

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07809913T PL2040713T3 (pl) 2006-06-27 2007-06-27 Pochodne kwasów żółciowych jako ligandy FXR do zapobiegania lub leczenia chorób lub stanów, w których pośredniczy FXR

Country Status (15)

Country Link
US (4) US7932244B2 (pl)
EP (1) EP2040713B1 (pl)
JP (1) JP5222846B2 (pl)
CN (1) CN101522703B (pl)
AU (1) AU2007265457C1 (pl)
CA (1) CA2656320C (pl)
CY (1) CY1115533T1 (pl)
DK (1) DK2040713T3 (pl)
ES (1) ES2523591T3 (pl)
HK (1) HK1130187A1 (pl)
IL (2) IL196169A (pl)
PL (1) PL2040713T3 (pl)
PT (1) PT2040713E (pl)
SI (1) SI2040713T1 (pl)
WO (1) WO2008002573A2 (pl)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1392714T3 (da) 2001-03-12 2006-01-09 Intercept Pharmaceuticals Inc Steroider som agonister for FXR
SI2712617T1 (sl) 2004-03-12 2017-01-31 Intercept Pharmaceuticals, Inc. Zdravljenje fibroze z uporabo Fxr ligandov
US10987362B2 (en) 2004-03-12 2021-04-27 Intercept Pharmaceuticals, Inc. Treatment of fibrosis using FXR ligands
ITMI20050912A1 (it) 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
EP2040713B1 (en) 2006-06-27 2014-06-18 Intercept Pharmaceuticals Inc. Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated deseases or conditions
CA2676417C (en) 2007-01-19 2016-06-28 Intercept Pharmaceuticals, Inc. Tgr5 modulators and methods of use thereof
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EA020310B1 (ru) * 2008-07-30 2014-10-30 Интерсепт Фармасьютикалз, Инк. Модуляторы рецептора tgr5 и их применение
JP5535233B2 (ja) 2008-11-19 2014-07-02 インターセプト ファーマシューティカルズ， インコーポレイテッド Ｔｇｒ５モジュレーターおよびその使用方法
CA2744697C (en) 2008-11-26 2016-06-21 Satiogen Pharmaceuticals, Inc. Use of compositions comprising bile acids, salts, and mimics thereof for the treatment of obesity or diabetes
WO2010062861A2 (en) 2008-11-26 2010-06-03 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of obesity and diabetes
WO2010069604A1 (en) 2008-12-19 2010-06-24 Royal College Of Surgeons In Ireland Treatment of diarrhoea
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US9719068B2 (en) 2010-05-06 2017-08-01 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
US20110294767A1 (en) 2010-05-26 2011-12-01 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
ITRM20100329A1 (it) * 2010-06-15 2011-12-16 Franco Baldelli Modulazione del recettore nucleare per i farnesoidi (fxr) con molecole agoniste per la prevenzione e trattamento di fenomeni aterosclerotici indotti da somministrazione di inibitori delle proteasi
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
EP2525223A1 (en) * 2011-05-19 2012-11-21 Universiteit Maastricht In vitro method for predicting in vivo genotoxicity of chemical compounds.
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
WO2013049595A1 (en) * 2011-09-29 2013-04-04 Ethicon Endo-Surgery, Inc. Methods and compositions of bile acids
US20140243281A1 (en) 2011-10-28 2014-08-28 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
EP2770990A4 (en) 2011-10-28 2015-03-11 Lumena Pharmaceuticals Inc Gallic acid refluxing agent for the treatment of hypertension and chronic liver disease
JP2015521621A (ja) 2012-06-19 2015-07-30 インターセプト ファーマシューティカルズ， インコーポレイテッド オベチコール酸の調製、使用および固体形態
US9982008B2 (en) 2012-06-19 2018-05-29 Intercept Pharmaceuticals, Inc. Preparation and uses of obeticholic acid
CN108250264A (zh) * 2012-10-26 2018-07-06 英特塞普特医药品公司 制备胆汁酸衍生物的方法
NZ708501A (en) * 2012-11-28 2019-03-29 Intercept Pharmaceuticals Inc Treatment of pulmonary disease
PL3360882T3 (pl) * 2013-05-14 2021-10-25 Intercept Pharmaceuticals, Inc. 11-hydroksy-6-podstawione pochodne kwasów żółciowych i ich koniugaty aminokwasowe jako modulatory receptorów farnezoidu X
WO2014200349A1 (en) 2013-06-13 2014-12-18 Fast Forward Pharmaceutical B.V. Cd40 signalling inhibitor and a further compound, wherein the further compound is a bile acid, a bile acid derivative, an tgr5-receptor agonist, an fxr agonist or a combination thereof, for the treatment of chronic inflammation, and the prevention of gastrointestinal cancer or fibrosis.
NZ716568A (en) * 2013-08-01 2021-07-30 Us Health Inhibitors of the farnesoid x receptor and uses in medicine
CN105764569B (zh) 2013-09-11 2019-09-13 国家医疗保健研究所 治疗乙型肝炎病毒感染的方法和药物组合物
MX356006B (es) * 2013-10-18 2018-04-24 Centro De Investig Y Asistencia En Tecnologia Y Diseno Del Estado De Jalisco A C Proceso para obtener una molécula que sirve como elicitor de péptidos antimicrobianos.
CA2930973A1 (en) 2013-11-22 2015-05-28 Pal SAERTROM C/ebp alpha short activating rna compositions and methods of use
SG10201801654RA (en) 2014-05-28 2018-04-27 Childrens Hospital Med Ct Methods and systems for converting precursor cells into gastric tissues through directed differentiation
HUE048351T2 (hu) 2014-05-29 2020-07-28 Bar Pharmaceuticals S R L Kolán-származékok alkalmazása FXR és TGR5/GPBAR1 mediált betegségek kezelésére és/vagy prevenciójára
KR20190035960A (ko) 2014-09-24 2019-04-03 길리애드 사이언시즈, 인코포레이티드 간 질환의 치료 방법
WO2016045480A1 (zh) * 2014-09-28 2016-03-31 上海源力生物技术有限公司 一种奥贝胆酸的制备方法
EP3207123A1 (en) 2014-10-17 2017-08-23 Children's Hospital Center D/b/a Cincinnati Children's Hospital Medical Center In vivo model of human small intestine using pluripotent stem cells and methods of making and using same
EP3215179A4 (en) 2014-11-06 2018-07-25 Enanta Pharmaceuticals, Inc. Bile acid analogs an fxr/tgr5 agonists and methods of use thereof
CN107207559B (zh) 2014-11-19 2019-10-25 Nzp英国有限公司 作为制备类固醇fxr调节剂的中间体的6-烷基-7-羟基-4-烯-3-酮类固醇
CA2968310A1 (en) 2014-11-19 2016-05-26 NZP UK Limited 6.alpha.-alkyl-6,7-dione steroids as intermediates for the production of steroidal fxr modulators
KR102526632B1 (ko) 2014-11-19 2023-04-27 엔제트피 유케이 리미티드 스테로이드 FXR 조절인자를 제조하기 위한 중간체로서의 5β-6-알킬-7-하이드록시-3-온 스테로이드
US10538550B2 (en) 2014-11-19 2020-01-21 NZP UK Limited 6.alpha.-alkyl-3,7-dione steroids as intermediates for the production of steroidal FXR modulators
US11578097B2 (en) 2014-11-26 2023-02-14 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
AU2015353473A1 (en) 2014-11-26 2017-06-08 Enanta Pharmaceuticals, Inc. Bile acid analogs as FXR/TGR5 agonists and methods of use thereof
EA036404B1 (ru) 2015-02-06 2020-11-06 Интерсепт Фармасьютикалз, Инк. Фармацевтические композиции для комбинированной терапии
RU2017130466A (ru) 2015-02-11 2019-03-12 Энанта Фармасьютикалс, Инк. Аналоги желчной кислоты в качестве агонистов fxr/tgr5 и способы их применения
LT3277286T (lt) 2015-03-31 2021-07-26 Enanta Pharmaceuticals, Inc. Tulžies rūgšties dariniai kaip fxr/tgr agonistai, ir jų panaudojimo būdai
JP6879931B2 (ja) 2015-04-07 2021-06-02 インターセプト ファーマシューティカルズ， インコーポレイテッド 併用療法用の医薬組成物
CN106083978A (zh) * 2015-04-28 2016-11-09 上海迪诺医药科技有限公司 磺酰基氨基羰基衍生物、其药物组合物及应用
EP3124080A1 (en) 2015-07-28 2017-02-01 Merz Pharma GmbH & Co. KGaA Semisynthetic bile acids for injection lipolysis
AU2016326428A1 (en) 2015-09-21 2018-04-12 Intercept Pharmaceuticals, Inc. Methods of promoting hepatic regeneration
AU2016325619A1 (en) * 2015-09-24 2018-04-12 Intercept Pharmaceuticals, Inc. Methods and intermediates for the preparation bile acid derivatives
EP3359160B1 (en) 2015-10-07 2021-08-25 Intercept Pharmaceuticals, Inc. Farnesoid x receptor modulators
IL243707A0 (en) 2016-01-20 2016-05-01 Galmed Res And Dev Ltd Treatment to regulate the microbiota in the intestine
WO2017142895A1 (en) * 2016-02-15 2017-08-24 Regents Of The University Of Minnesota Compositions and methods for treating clostridium associated diseases
US20170233431A1 (en) * 2016-02-17 2017-08-17 City Of Hope Bile acid derivatives and methods for synthesis and use
WO2017147159A1 (en) 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Deuterated bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
US10323060B2 (en) 2016-02-23 2019-06-18 Enanta Pharmaceuticals, Inc. Benzoic acid derivatives of bile acid as FXR/TGR5 agonists and methods of use thereof
WO2017147174A1 (en) 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Heteroaryl containing bile acid analogs as fxr/tgr5 agonists and methods of use thereof
MX2018011813A (es) 2016-03-28 2019-01-24 Intercept Pharmaceuticals Inc Medicina obtenida mediante la combinacion de agonista fxr y arb.
IL262342B (en) * 2016-04-13 2022-08-01 Intercept Pharmaceuticals Inc An fxr agonist for use as a medicament for the treatment or prevention of hepatocellular carcinoma
CN116790476A (zh) 2016-05-05 2023-09-22 儿童医院医疗中心 用于体外制造胃底组织的方法和与其相关的组合物
GB201608776D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Methods and compounds
GB201608777D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Compounds
CA2968836A1 (en) 2016-06-13 2017-12-13 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
SG11201810600WA (en) 2016-06-13 2018-12-28 Gilead Sciences Inc Fxr (nr1h4) modulating compounds
WO2018064441A1 (en) * 2016-09-30 2018-04-05 Intercept Pharmaceuticals, Inc Crystalline forms of a bile acid derivative
WO2018085622A1 (en) 2016-11-04 2018-05-11 Children's Hospital Medical Center Liver organoid disease models and methods of making and using same
US11197870B2 (en) 2016-11-10 2021-12-14 Galmed Research And Development Ltd Treatment for hepatic fibrosis
US10584145B2 (en) 2016-11-29 2020-03-10 Enanta Pharmaceuticals, Inc. Process for preparation of sulfonylurea bile acid derivatives
CN110062764B (zh) 2016-12-05 2024-07-02 儿童医院医学中心 结肠类器官及其制备和使用方法
WO2018152171A1 (en) 2017-02-14 2018-08-23 Enanta Pharmaceuticals, Inc. Bile acid derivatives as fxr agonists and methods of use thereof
TW201832768A (zh) * 2017-03-07 2018-09-16 英特賽普醫藥品公司 治療癌症的方法
US20180256600A1 (en) * 2017-03-07 2018-09-13 Intercept Pharmaceuticals, Inc. Methods of treating cancer
PL4122464T3 (pl) 2017-03-28 2024-09-16 Gilead Sciences, Inc. Kombinacje terapeutyczne do leczenia chorób wątroby
JP2020515564A (ja) 2017-03-30 2020-05-28 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル エピソーマルウイルスの持続性及び発現を低下させるための方法及び医薬組成物
ES2971092T3 (es) 2017-04-07 2024-06-03 Enanta Pharm Inc Procedimiento para la preparación de derivados de ácidos biliares de carbamato de sulfonilo
BR112020001362A2 (pt) 2017-07-24 2020-08-11 Intercept Pharmaceuticals, Inc. derivados de ácido biliar isotopicamente marcados
CA3075219A1 (en) 2017-09-08 2019-03-14 Mina Therapeutics Limited Hnf4a sarna compositions and methods of use
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
US11208571B2 (en) 2018-08-08 2021-12-28 University Of Maryland, College Park Methods for nondestructive dispersing of carbon nanomaterials in water
HUE065889T2 (hu) 2019-01-15 2024-06-28 Gilead Sciences Inc Izoxazol vegyület mint FXR agonista és az azt tartalmazó gyógyszerészeti készítmények
EP3920937A4 (en) * 2019-02-04 2022-11-02 Intercept Pharmaceuticals, Inc. TREATMENT AND PREVENTION OF INFLAMATORY BOWEL DISEASES WITH A BILE ACID DERIVATIVE
CA3233305A1 (en) 2019-02-19 2020-08-27 Gilead Sciences, Inc. Solid forms of fxr agonists
CN114144185A (zh) 2019-05-30 2022-03-04 英特塞普特医药品公司 用于治疗胆汁淤积性肝病的包含fxr激动剂和贝特类的药物组合物
CN112142814B (zh) * 2019-06-26 2021-09-28 江苏吉贝尔药业股份有限公司 牛磺熊去氧胆酸衍生物以及包含其的药物组合物和制剂
CA3139291A1 (en) 2019-07-18 2021-01-21 Jacky Vonderscher Method for decreasing adverse-effects of interferon
WO2021144330A1 (en) 2020-01-15 2021-07-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of fxr agonists for treating an infection by hepatitis d virus
CN117202905A (zh) 2021-01-14 2023-12-08 埃尼奥制药公司 Fxr激动剂和ifn用于治疗hbv感染的协同效果
EP4329761A1 (en) 2021-04-28 2024-03-06 ENYO Pharma Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5014206A (en) 1988-08-22 1991-05-07 Facilitech International Incorporated Tracking system
DE9011787U1 (de) 1990-08-14 1990-10-25 Fritz Schäfer GmbH, 5908 Neunkirchen Identifikationseinheit für Müllbehälter
US5121853A (en) 1991-07-30 1992-06-16 Waste Management Of North America Garbage container
DE9204254U1 (de) 1992-03-28 1992-06-17 Fritz Schäfer GmbH, 5908 Neunkirchen Müllbehälter, insbesondere Müllgroßraumbehälter, mit einer Identifikationseinheit
ZA947912B (en) 1993-10-12 1995-05-24 Broadbent J W Nominees Pty Ltd Treatment of medical disorders associated with free radical formation
US5541348A (en) 1994-03-10 1996-07-30 National Research Council Of Canada Bile acids for biological and chemical applications and processes for the production thereof
US5565846A (en) 1994-04-25 1996-10-15 Indala Corporation Reader system for waste bin pickup vehicles
FR2784364B1 (fr) 1998-10-13 2000-12-15 Plastic Omnium Cie Bac pour la collecte de dechets, equipe d'un transpondeur
JP2002532729A (ja) 1998-12-23 2002-10-02 グラクソ グループ リミテッド 核内受容体のリガンドのアッセイ
US6448898B1 (en) 1999-12-16 2002-09-10 Cardinal Automation, Inc. System for auditing refuse collection
DE10030905C2 (de) 2000-06-24 2003-08-07 Der Gruene Punkt Duales Syst Verwendung von Transpondern bei der Dokumentation und Handhabung von Abfällen
DK1392714T3 (da) * 2001-03-12 2006-01-09 Intercept Pharmaceuticals Inc Steroider som agonister for FXR
US7078396B2 (en) * 2001-05-03 2006-07-18 Arch Development Corporation Method of treating disorder related to high cholesterol concentration
JP5384777B2 (ja) 2001-12-18 2014-01-08 有限会社大長企画 強筋肉剤、抗炎症剤
US6975229B2 (en) 2002-08-09 2005-12-13 Battelle Memorial Institute K1-53 System and method for acquisition management of subject position information
US20040229453A1 (en) * 2003-05-15 2004-11-18 Jsr Micro, Inc. Methods of pore sealing and metal encapsulation in porous low k interconnect
EP1568706A1 (en) * 2004-02-26 2005-08-31 Intercept Pharmaceuticals, Inc. Novel steroid agonist for FXR
EP2040713B1 (en) 2006-06-27 2014-06-18 Intercept Pharmaceuticals Inc. Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated deseases or conditions

Also Published As

Publication number Publication date
CN101522703A (zh) 2009-09-02
US9763964B2 (en) 2017-09-19
AU2007265457B2 (en) 2012-06-14
AU2007265457A1 (en) 2008-01-03
EP2040713B1 (en) 2014-06-18
CN101522703B (zh) 2013-04-17
US20140057886A1 (en) 2014-02-27
US20120283234A1 (en) 2012-11-08
CA2656320A1 (en) 2008-01-03
JP2010500285A (ja) 2010-01-07
ES2523591T3 (es) 2014-11-27
CY1115533T1 (el) 2017-01-04
JP5222846B2 (ja) 2013-06-26
IL221764A (en) 2016-09-29
IL221764A0 (en) 2012-10-31
PT2040713E (pt) 2014-10-13
IL196169A0 (en) 2009-09-22
US9090652B2 (en) 2015-07-28
WO2008002573A2 (en) 2008-01-03
EP2040713A4 (en) 2012-08-29
HK1130187A1 (en) 2009-12-24
US7932244B2 (en) 2011-04-26
SI2040713T1 (sl) 2014-11-28
EP2040713A2 (en) 2009-04-01
DK2040713T3 (da) 2014-09-29
WO2008002573A3 (en) 2008-02-28
US20150359805A1 (en) 2015-12-17
US20080182832A1 (en) 2008-07-31
IL196169A (en) 2012-10-31
US8546365B2 (en) 2013-10-01
CA2656320C (en) 2015-04-28
AU2007265457C1 (en) 2012-11-29

Similar Documents

Publication Publication Date Title
PL2040713T3 (pl) Pochodne kwasów żółciowych jako ligandy FXR do zapobiegania lub leczenia chorób lub stanów, w których pośredniczy FXR
HUS1800006I1 (hu) Alfa-MSH származékok fotodermatózisok kezelésére
PL2118074T3 (pl) Związki chemiczne do celów profilaktyki i leczenia chorób układu sercowo-naczyniowego
PT2474321T (pt) Composições adequadas ao tratamento de doenças mediadas pelo colagenio
IL187565A0 (en) Compositions and methods for the treatment or prevention of chemoresistant neoplasia
ZA201001264B (en) 1-amino-alkylcycohxane derivatives for the treatment of cochleat tinnitus
WO2007101161A8 (en) Methods and compositions for the treatment of gastrointestinal disorders
PL3216457T3 (pl) Związki i sposoby zapobiegania lub leczenia restenozy
ZA200904573B (en) Compositions comprising bile acid sequestrants for treating esophageal disorders
GB0909297D0 (en) Composition for the treatment of skin conditions
SI2234631T1 (sl) Spojine in postopki za zdravljenje ĺ˝ilne bolezni
IL192933A0 (en) Benzoisoindole derivatives for the treatment of pain
EP2231146A4 (en) Pharmaceutical composition for the treatment and prevention of glaucoma
HK1185345A1 (zh) 用於預防和治療心血管疾病的化合物
GB0808730D0 (en) Compositions and methods for the prevention and treatment of schistosomiasis
IL208231A0 (en) Agent for preventing and/or treating vascular diseases
GB0617280D0 (en) Compositions and methods for the treatment of neurological damage
ZA200806180B (en) Benzoisoindole derivatives for the treatment of pain
IL197485A0 (en) Use of vitamin d compounds for the prevention of adhesions
GB0601091D0 (en) The Treatment Of Ocular Conditions
AU2008905198A0 (en) Compositions and Methods for the Prevention and Treatment of Cancer
AU2008903693A0 (en) Compositions and methods for the prevention and treatment of cancer
ZA200805398B (en) Use of kcnq-openers for treating or reducing the symptons of schizophrenia
GB0608007D0 (en) Preparation for the treatment of burns
ZA200605368B (en) Gallic acid derivative and process of preparing the same